中南医学科学杂志2025，Vol.53Issue(2)：272-275,4.DOI:10.15972/j.cnki.43-1509/r.2025.02.019
MPVLR对PD-1抑制剂联合恩度治疗晚期NSCLC预后的评估价值
Evaluation value of MPVLR in predicting the prognosis of advanced NSCLC treated with PD-1 inhibitor combined with Endostar
摘要
Abstract
Aim To explore the evaluation value of mean platelet volume to lymphocyte ratio(MPVLR)in predicting the prognosis of advanced non-small cell lung cancer(NSCLC)treated with PD-1 inhibitor combined with Endostar.Methods A to-tal of 75 patients with advanced NSCLC treated with PD-1 inhibitor combined with Endostar were selected and divided into a good prog-nosis group(52 cases)and a poor prognosis group(23 cases)based on prognosis.According to the MPVLR cutoff value,patients were further divided into a low MPVLR group(45 cases)and a high MPVLR group(30 cases).Baseline data,MPVLR levels,and prognosis were compared between groups.Multivariate COX regression analysis was used to identify factors affecting prognosis,and ROC curve analysis was performed to evaluate the predictive value of MPVLR for patient prognosis.Results There were signifi-cant differences in TNM stage,KPS score,eastern cooperative oncology group score,number of metastatic sites,treatment lines,and MPVLR between the good prognosis group and the poor prognosis group(P＜0.05).The MPVLR level in the poor prognosis group was higher than that in the good prognosis group(P＜0.05).The progression free survival in the high MPVLR group was lower than that in the low MPVLR group(P＜0.001).The number of metastatic sites ≥3,treatment lines ≥3,and MPVLR＞5.319,were all risk factors for patient prognosis(P＜0.05).MPVLR had a good predictive value for patient prognosis(P＜0.05).Conclusion MPVLR has a good evaluation value in predicting the prognosis of advanced NSCLC patients treated with PD-1 inhibitor combined with Endostar.关键词
平均血小板体积/淋巴细胞比值/PD-1抑制剂/晚期/非小细胞肺癌/预后Key words
mean platelet volume to lymphocyte ratio/PD-1 inhibitor/advanced/non-small cell lung cancer/prognosis分类
临床医学引用本文复制引用
贾同磊,许艳辉,曹新超,贺丽君,马平..MPVLR对PD-1抑制剂联合恩度治疗晚期NSCLC预后的评估价值[J].中南医学科学杂志,2025,53(2):272-275,4.基金项目
河北省医学科学研究项目(20242172) （20242172）
